# MariTide

Canonical source: https://retacompare.com/encyclopedia/maritide

GIPR antagonism plus GLP-1R agonism delivered as a single antibody-peptide conjugate. Monthly subcutaneous dosing.

Reference facts

Also known asAMG 133, Maridebart cafraglutideCategoryGLP-1 & MetabolicMechanism of actionGIPR antagonism plus GLP-1R agonism delivered as a single antibody-peptide conjugate. Monthly subcutaneous dosing.TargetsGIPR (antagonist), GLP-1R (agonist)Indications under research or approvedObesity, Type 2 DiabetesRegulatory status (reference entry)Investigational (Phase 3 MARITIME)Half-life~21 daysSequence notesPeptide-antibody conjugate: monoclonal anti-GIPR antibody covalently linked to two GLP-1 analog peptides via stable conjugation.Molecular weight (Da)150000Originator / sponsorAmgenFirst reported2023
    Primary References

AMG 133 Phase 1, Nat Metab 2024

MARITIME-1 (NCT06469281)


    Explore research articles about MariTide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- AMG 133 Phase 1, Nat Metab 2024: https://www.nature.com/articles/s42255-024-01092-x
- MARITIME-1 (NCT06469281): https://clinicaltrials.gov/study/NCT06469281